Lansforsakringar Fondforvaltning AB publ Lowers Holdings in Eli Lilly and Company $LLY

Key Points

• Lansforsakringar Fondforvaltning AB publ has reduced its position in Eli Lilly and Company by 1.2%, making it the 7th largest holding in their investment portfolio, which is valued at approximately $286 million.
• Wall Street analysts show strong confidence in Eli Lilly, with many upgrading their ratings, leading to a consensus rating of "Moderate Buy" and an average price target of $950.17.
• Insider purchases have been noted, with significant acquisitions by the EVP and CEO on August 12, indicating ongoing executive confidence in Eli Lilly's future.

Lansforsakringar Fondforvaltning AB publ trimmed its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 1.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 346,424 shares of the company's stock after selling 4,148 shares during the quarter. Eli Lilly and Company accounts for approximately 1.8% of Lansforsakringar Fondforvaltning AB publ's holdings, making the stock its 7th biggest holding. Lansforsakringar Fondforvaltning AB publ's holdings in Eli Lilly and Company were worth $286,115,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in LLY. Corient IA LLC purchased a new position in shares of Eli Lilly and Company during the first quarter valued at about $570,000. LS Investment Advisors LLC increased its position in shares of Eli Lilly and Company by 1.7% during the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock valued at $1,933,000 after buying an additional 40 shares during the period. Prism Advisors Inc. purchased a new position in shares of Eli Lilly and Company during the first quarter valued at about $207,000. Hemington Wealth Management increased its position in shares of Eli Lilly and Company by 14.4% during the first quarter. Hemington Wealth Management now owns 985 shares of the company's stock valued at $813,000 after buying an additional 124 shares during the period. Finally, Bfsg LLC increased its position in shares of Eli Lilly and Company by 1.4% during the first quarter. Bfsg LLC now owns 2,959 shares of the company's stock valued at $2,444,000 after buying an additional 42 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 0.1%

LLY stock traded up $0.45 during trading on Friday, hitting $732.41. 2,548,350 shares of the stock traded hands, compared to its average volume of 6,895,566. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $969.65. The firm's 50 day moving average is $748.68 and its two-hundred day moving average is $785.49. The stock has a market cap of $693.20 billion, a price-to-earnings ratio of 47.87, a price-to-earnings-growth ratio of 1.02 and a beta of 0.44. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the firm posted $3.92 EPS. Eli Lilly and Company's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is 39.22%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on LLY shares. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Leerink Partners reaffirmed a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Daiwa Capital Markets downgraded shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price on the stock. in a research report on Sunday, August 17th. HSBC raised shares of Eli Lilly and Company from a "reduce" rating to a "hold" rating and upped their target price for the stock from $675.00 to $700.00 in a research report on Wednesday. Finally, Wall Street Zen raised shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research report on Saturday. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $950.17.

Insider Activity at Eli Lilly and Company

In related news, EVP Daniel Skovronsky bought 1,000 shares of the stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares of the company's stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director J Erik Fyrwald bought 1,565 shares of the stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock worth $2,894,841 in the last ninety days. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.